Description

CJC-1295 2mg WITH DAC: Research-Grade Long-Acting GHRH Analogue

CJC-1295 with DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH) engineered with a Drug Affinity Complex (DAC) to dramatically extend its plasma half-life compared to native GHRH or short-acting analogues . The DAC modification enables reversible binding to serum albumin, protecting the peptide from enzymatic degradation and reducing renal clearance . This design results in a circulating half-life of approximately 6 to 8 days in research settings .

The peptide is a 29-amino acid analogue based on the first 29 residues of human GHRH, incorporating structural modifications that enhance stability against proteolytic degradation . It retains high affinity for the GHRH receptor while achieving sustained receptor activation .

Mechanism of Action

GHRH Receptor Signaling

CJC-1295 binds to GHRH receptors on somatotroph cells of the anterior pituitary gland, triggering a signaling cascade via Gs-protein coupling, cAMP accumulation, and protein kinase A (PKA) phosphorylation . This stimulates GH gene transcription and pulsatile GH secretion into systemic circulation. As CJC-1295 acts on an upstream receptor rather than delivering GH directly, the pituitary’s own somatostatin-mediated feedback loop remains operational, limiting supraphysiological excursions .

DAC: Albumin Conjugation and Extended Half-Life

The DAC variant’s extended half-life derives from specific covalent chemistry. After subcutaneous injection, the maleimido group on the biotin linker reacts with the free thiol on cysteine-34 of circulating albumin to form a stable thioether bond . Since albumin has a plasma half-life of approximately 19 days, once CJC-1295 DAC is conjugated to it, the peptide is protected from renal filtration and proteolytic clearance, circulating with albumin’s pharmacokinetic profile .

Pharmacodynamic Effects

In research settings, a single dose of CJC-1295 with DAC produces:

• GH Elevation: 2- to 10-fold increase in plasma GH levels 

• IGF-1 Elevation: 1.5- to 3-fold increase above baseline, sustained for 9-11 days 

• Extended Duration: IGF-1 levels remain elevated for up to 11 days post-injection, with repeated doses maintaining elevation for up to 28 days 

• Pulsatile Profile: 3-4 GH peaks over 6-8 days, mirroring physiological pulsatility at higher amplitudes 

Product Features

• 2 mg Research Unit Size: Suitable for laboratory protocols

• >99% Purity by HPLC: Manufactured to rigorous standards 

• Lyophilized Format: Stable powder for reliable reconstitution

• DAC Modification: Extends half-life to 6-8 days for sustained research applications 

• Long-Acting GHRH Analogue: Enables weekly dosing in research protocols 

• Research-Grade Quality: Intended solely for investigational purposes 

Research Applications

This product is suitable for laboratory research and preclinical studies in the following areas:

• GH Axis Modulation Studies: Investigating prolonged GHRH receptor engagement and sustained GH/IGF-1 secretion dynamics 

• Endocrine Signaling Research: Characterizing GHRH receptor signaling pathways and feedback mechanisms 

• Metabolic Regulation Research: Studying the effects of sustained GH elevation on lipid metabolism, glucose regulation, and protein synthesis 

• Anti-Aging and Tissue Repair Research: Investigating GH/IGF-1 axis modulation and its effects on connective tissue repair, collagen synthesis, and bone density 

• Pharmacokinetic Modeling: Studying the impact of DAC-mediated albumin binding on peptide stability and biodistribution 

• Combination Therapy Models: Often used in conjunction with GHS-R agonists (e.g., Ipamorelin, GHRP-2, GHRP-6) to investigate synergistic effects on GH secretion 

CJC-1295 WITH DAC vs WITHOUT DAC: Critical Distinction

The two primary variants of CJC-1295 differ fundamentally in their pharmacokinetics and research applications :

The choice between variants depends on the research objective: sustained GH elevation favours the DAC variant, while acute pulsatile GH secretion favours the non-DAC variant .

Recommended Use

This product is intended solely for laboratory research purposes. The lyophilized powder must be reconstituted using sterile technique.

Reconstitution Instructions

1. Briefly centrifuge the vial before opening to bring contents to the bottom

2. Reconstitute with sterile water or bacteriostatic water to desired concentration

3. Gently swirl until completely dissolved; do not vortex or shake vigorously

4. Apportion stock solutions into working aliquots for research protocols

5. For a 1 mg/mL concentration, add 2 mL of sterile water to the 2 mg vial 

Research Dosing Considerations

Typical research protocols employ:

• CJC-1295 with DAC: 1-2 mg per injection, administered once every 5-7 days 

• Combined Protocols: When combined with Ipamorelin, CJC-1295 with DAC (1-2 mg weekly) may be administered alongside 100-300 mcg of Ipamorelin daily 

Administration Timing

Many protocols administer compounds in the evening to synchronise with the natural circadian rhythm of GH secretion, potentially creating more physiologically relevant GH elevation profiles .

Storage Instructions

Lyophilized Powder:

• Storage: Store at 2–8°C (refrigerated) 

• Protect from Light: Keep in original packaging 

• Shelf Life: Stable for up to 12 months at 2–8°C when stored as lyophilized powder 

Reconstituted Solution:

• Storage: Refrigerate at 2–8°C 

• Use Within: 14 days of reconstitution when stored at 2–8°C 

• Do Not Freeze: Avoid freeze-thaw cycles 

• Do Not Shake: Avoid vigorous shaking

Regulatory and Research Status

• CJC-1295 with DAC is not FDA-approved for any therapeutic indication 

• As of April 2026, CJC-1295 is classified as an FDA 503A Category 2 bulk drug substance, prohibited for use in compounding by licensed pharmacies in the United States 

• ConjuChem withdrew CJC-1295 with DAC from clinical trials in 2006 

• The compound is available through non-US licensed channels and in research contexts 

• CJC-1295 and its analogues are included in the World Anti-Doping Agency (WADA) prohibited list 

• No completed Phase 2 or Phase 3 RCTs exist for any indication 

Research Use Disclaimer

This product is intended solely for laboratory research purposes. It is not suitable for human or animal consumption, nor for medical, veterinary, or household applications . It is not authorised by the MHRA, EMA, FDA, or other medicines regulators for any therapeutic indication or clinical application . Researchers should adhere to appropriate safety protocols, institutional guidelines, and applicable laws and ethical approvals .

Top 10 Frequently Asked Questions

1. What is CJC-1295 with DAC?
CJC-1295 with DAC is a synthetic analogue of growth hormone-releasing hormone (GHRH) modified with a Drug Affinity Complex (DAC) that extends its plasma half-life to approximately 6-8 days .

2. What does the DAC do?
The DAC (Drug Affinity Complex) enables reversible binding to serum albumin, protecting the peptide from enzymatic degradation and reducing renal clearance. This extends the peptide’s half-life from minutes to days .

3. What is the half-life of CJC-1295 with DAC?
The plasma half-life is approximately 6-8 days . The apparent half-life for pharmacodynamic GH release effect is approximately 8 days .

4. How does CJC-1295 with DAC differ from CJC-1295 without DAC?
CJC-1295 with DAC has a 6-8 day half-life allowing weekly dosing, while without DAC has a 30-60 minute half-life requiring multiple daily doses. The DAC variant produces sustained GH elevation, while the non-DAC variant produces acute pulses .

5. What is the research dosing protocol for CJC-1295 with DAC?
Typical research protocols use 1-2 mg per injection, administered once every 5-7 days .

6. What are the primary research applications for CJC-1295 with DAC?
It is used in GH axis modulation studies, endocrine signaling research, metabolic regulation research, anti-aging and tissue repair research, and pharmacokinetic modeling .

7. What are the purity standards for this product?
Research-grade CJC-1295 with DAC is manufactured to >99% purity as determined by HPLC .

8. What are the phase I clinical trial findings for CJC-1295 with DAC?
The 2006 Teichman Phase 1 trial demonstrated that a single subcutaneous dose produced dose-dependent mean GH elevations of 2- to 10-fold and sustained IGF-1 elevations of 1.5- to 3-fold above baseline lasting 9-11 days . However, no completed Phase 2 or Phase 3 efficacy trials exist .

9. What is the regulatory status of CJC-1295 with DAC?
CJC-1295 with DAC is not FDA-approved for any therapeutic indication. As of April 2026, it is classified as an FDA 503A Category 2 bulk drug substance, prohibited for use in compounding by licensed pharmacies in the United States . ConjuChem withdrew it from clinical trials in 2006 .

10. Is CJC-1295 with DAC suitable for human use?
No. This product is intended solely for laboratory research purposes and is not suitable for human or animal consumption . It is classified for investigational use only and has no approval from the U.S. FDA, EMA, or other major regulatory authorities .

---

Ready to take the next step?
Secure your supply of CJC-1295 2mg WITH DAC from a trusted source. Visit anabolicsteroidsonline.shop today to explore our selection of premium research products.